TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06368453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI® HIV Self-Test
Description: Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing.
Study: NCT04712604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) Program
Description: MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
Study: NCT05011513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (capsule)
Study: NCT06420154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion
Study: NCT05441722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation
Description: Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
Study: NCT06394427

Intervention type: OTHER
Intervention: cycles of neoadjuvant therapy and duration of waiting for surgery
Description: We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Intervention type: OTHER
Intervention: cycles of neoadjuvant therapy and duration of waiting for surgery
Description: We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
Study: NCT04693481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature exposure
Description: Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature exposure
Description: Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature exposure
Description: Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
Study: NCT04979117

Intervention type: DEVICE
Intervention: Superb Microvascular Imaging (SMI) (Toshiba)
Description: to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.

Intervention type: DEVICE
Intervention: Superb Microvascular Imaging (SMI) (Toshiba)
Description: to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
Study: NCT06044857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Will be injected/assessed in line with its FDA label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Will be injected/assessed in line with its FDA label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Will be injected/assessed in line with its FDA label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Will be injected/assessed in line with its FDA label.
Study: NCT05725083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower thoracic epidural
Description: before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
Study: NCT05508412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CancerPEP
Description: CancerPEP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CancerPEP
Description: CancerPEP
Study: NCT05705063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Ketogenic Diet
Description: Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
Study: NCT05664724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receives interdisciplinary sessions
Description: Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members.
Study: NCT05483491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KK-LC-1 TCR-T cells
Description: Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study: NCT04466475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given via infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplantation
Study: NCT06242210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pursed lip
Description: pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stacked Breathing
Description: The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
Study: NCT05936801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior Chest Compression technique
Description: Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Thrust Technique
Description: Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
Study: NCT06145841

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathogen metagenomic next-generation sequencing
Description: In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
Study: NCT05179811

Intervention type: PROCEDURE
Intervention: Hypnosis sessions
Description: * Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire
Study: NCT05286177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume-based EN
Description: Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for \> 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rate-based EN
Description: Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
Study: NCT04561700

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reporting of sucking patterns captured by Instrumented Bottle
Description: In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
Study: NCT05210959

Intervention type: OTHER
Intervention: The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Description: The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
Study: NCT06217913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable device to monitor the blood pressure
Description: Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.
Study: NCT05637216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 25 milligram capsule
Description: Losartan 25 milligram oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 25 milligram capsule
Description: Losartan 25 milligram oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 milligram oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 milligram oral capsule
Study: NCT03692507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and HMB
Description: Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
Study: NCT05943717

Intervention type: DEVICE
Intervention: lung ultrasound and electrical cardiometry
Description: : B-lines of lung ultrasound and the parameters of cardiometry will be measured at the mid-week HD session before starting the session by 30 min then every 30min during HD session for 180 min and then after the end of the session of HD by 30 min and then The specificity and sensitivity of both techniques will be compared to each other
Study: NCT04748484

Intervention type: DEVICE
Group type: OTHER
Intervention: KCC Active or inactive
Description: Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
Study: NCT01885676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRGF-Endoret
Description: PRGF-Endoret mesotherapy micro injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution mesotherapy micro injection
Study: NCT06124378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: The specific surgical approach is laparoscopic. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
Study: NCT06411574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Alimetry
Description: The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
Study: NCT05205174

Intervention type: DEVICE
Group type: OTHER
Intervention: depth electrodes
Description: The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
Study: NCT05411744

Intervention type: DRUG
Group type: OTHER
Intervention: 1 month Rifapentine, Isoniazid and Vitamin B6
Description: Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
Study: NCT02039869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Description: The probe allows microscopic evaluation of tissue in real time during endoscopy.
Study: NCT06190808

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitor
Description: Continuous glucose monitor
Study: NCT02039869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Description: The probe allows microscopic evaluation of tissue in real time during endoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Description: Acid suppressing medication (over the counter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Coating agent for damaged intestinal lining.
Study: NCT05626556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAVE system
Description: The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
Study: NCT05858216

Intervention type: DRUG
Group type: OTHER
Intervention: Chlor-Trimeton.
Description: Package dose of Chlor-Trimeton will be administered
Study: NCT06084793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
Study: NCT03957161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of ACEi and/or ARBs
Description: Patients will continue or start taking ACEi and/or ARBs
Study: NCT05741242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Synthetic Long Peptide Vaccine
Description: Personalized Synthetic Long Peptide Vaccine
Study: NCT04670991

Intervention type: RADIATION
Group type: OTHER
Intervention: EXATRAC imaging
Description: Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
Study: NCT05404269

Intervention type: DEVICE
Intervention: AGC mode
Description: Automated Gas Control mode at Maquet FLOW-i anesthesia machine